Last update 01 Nov 2024

Short Stature, Idiopathic, Autosomal

Last update 01 Nov 2024

Basic Info

Synonyms

GHDP, GHIP, GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL

+ [5]

Introduction-

Drugs associated with Short Stature, Idiopathic, Autosomal

Recombinant human growth hormone(Changchun Genescience)

Target

GHR

Mechanism

GHR agonists

Active Org.

Changchun Genescience Pharmaceuticals Co., Ltd.

Originator Org.

Changchun Genescience Pharmaceuticals Co., Ltd.

Active Indication

Short Stature, Idiopathic, Autosomal [+4]

Inactive Indication

Chronic Kidney Diseases [+3]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jan 1998

AK2017

Target

Mechanism

GR agonists

Active Org.

Anhui Anke Biotechnology (Group) Co., Ltd.

Originator Org.

Anhui Anke Biotechnology (Group) Co., Ltd.

Active Indication

Growth hormone deficiency [+3]

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with Short Stature, Idiopathic, Autosomal

100 Translational Medicine associated with Short Stature, Idiopathic, Autosomal

0 Patents (Medical) associated with Short Stature, Idiopathic, Autosomal

125

Literatures (Medical) associated with Short Stature, Idiopathic, Autosomal

08 Mar 2024·Zhonghua bing li xue za zhi = Chinese journal of pathology

[Gastric hamartomatous inverted polyps: a clinicopathological analysis of five cases].

Article

Author: Hong, M ; Lin, X F ; Yang, H F ; Zhao, J ; Zhang, Z F ; Du, Z H

Objective: To investigate the endoscopic and histopathological features, diagnosis and differential diagnosis of gastric hamartomatous inverted polyp (GHIP). Methods: Five cases of GHIP were collected at the University Town Hospital of Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China, from May 2021 to May 2023. The endoscopic, pathological and immunohistochemical features of the 5 GHIP cases were analyzed. The relevant literature was reviewed. Results: There were 3 males and 2 females, aged from 49 to 60 years, with a mean age of 56 years. The lesions were located in the fundus and body of the stomach, and presented as polyps or masses under endoscopy. Microscopically, the lesions were mainly in the submucosa and consisted of lobulated or clustered gastric glandular epithelium surrounded by hyperplastic smooth muscle. In some areas, there were differentiated glandular elements mimicking the normal gastric mucosa. The irregularly dilated glandular elements in the center were lined by hyperplastic foveolar epithelium, while the glands in the periphery were fundic or pyloric glands. In addition, in some areas, the glands showed cystic expansion, disordered arrangement and lack of differentiation. The hyperplastic glandular epithelium included foveolar epithelium, fundic gland and pyloric gland. There were scattered neuroendocrine cells and smooth muscle bundles in the stroma. Immunohistochemically, the tumor cells were positive for MUC5AC, MUC6, Pepsinogen Ⅰ and H⁺/K⁺ ATPase β, but negative for MUC2. The scattered neuroendocrine cells were positive for synaptophysin, and the desmin stain highlighted hyperplastic smooth muscle bundles. One case was classified as type 2 gastric inverted polyp, and 4 cases were classified as type 3. Conclusions: GHIP is a rare gastric polyp with unique histological features. It should be distinguished from inverted hyperplastic polyp, gastritis cystica profunda, adenomyoma, hyperplastic polyps and well-differentiated gastric tubular adenocarcinoma, etc. Improving the understanding of its pathogenesis and diagnostic features can help avoid misdiagnoses.

01 Feb 2024·Cureus

Rathke’s Cleft Cyst Leads to Stunted Growth in Children: A Case Report Written With the Help of ChatGPT

Author: Huang, Huanxiang ; Li, Ziqi ; Xiao, Yong ; Wang, Shousen ; Li, Jun

In recent times, ChatGPT has become a globally renowned AI tool, revolutionizing academic research by offering innovative methods and opportunities. The integration of AI into various domains is a prevailing topic, focusing on optimizing its utility. This article presents a case study of a child with Rathke's cyst, primarily exhibiting symptoms of growth and developmental delay. The patient's self-perception of stunted growth, coupled with previous assessments indicating partial growth hormone deficiency, prompted further investigation. Laboratory assessments revealed low growth hormone and insulin-like growth factor levels, while imaging disclosed a pituitary lesion. Rathke's cyst was postulated as the probable cause of the growth hormone deficiency. Rathke's cyst remains a rare medical condition with substantial research knowledge gaps. In this article, we synergize ChatGPT responses with a comprehensive case report of a child with Rathke's cyst as the primary symptom-growth and developmental delay. We explore the methods and feasibility of employing ChatGPT within this case report.

29 Jan 2024·Journal of Pediatric Endocrinology and Metabolism

Ambulatory blood pressure monitorisation in children with recombinant growth hormone treatment

Article

Author: Aytaç Kaplan, Emel Hatun ; Onal, Hasan ; Kocabey Sütçü, Zümrüt ; Soyaltın, Eren

AbstractObjectivesIt is safe to use recombinant growth hormone in children. Studies have shown it to be effective and safe, except for a few side effects in the short and long term after treatment. The present study investigated the presence of hypertension in pediatric patients receiving growth hormone treatment using 24 h ambulatory blood pressure monitoring (ABPM).MethodsThis study is a single-center, retrospective study. Eighty-four patients aged 5–16 years who received growth hormone treatment for at least 3 months, who underwent 24 h ABPM were analyzed. They were compared with 67 patients who had no risk factors for hypertension.ResultsIn the study, 84 rhGH-treated patients (45.2 % male, 54.8 % female) and 67 healthy control groups (49.3 % male, 50.7 % female) were analyzed. The mean age of the patient group was 10.83±2.85 years and the mean age of the healthy control group was 13.1±2.93 years. The diagnostic classification of the patients receiving treatment was as follows: 66.6 % (n=56) partial growth hormone deficiency, 22.6 % (n=19) growth hormone deficiency, 7.1 % (n=6) bioactive growth hormone, 2.3 % (n=2) idiopathic short stature, 1.1 % (n=1) low birth weight for gestational age (SGA). Body mass index was significantly lower in the treated group (p=0.013). The duration of treatment was 6.04±4.9 months. Daytime diastolic blood pressure was significantly lower in the treated group (p=0.001). There was no correlation between BMI and ABPM parameters in the treatment group and the control group.ConclusionsThe present study shows that growth hormone treatment is safe in terms of high blood pressure.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Short Stature, Idiopathic, Autosomal

Basic Info

Related

Analysis